ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years
Hao Wang
Matched on ORCID iD 0000-0001-6881-9977; OpenAlex author ID A5100446035.
Their work
Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.
- Pancreatic cancer papers
- 13 (first author 2, last author 0)
- Pancreatic cancer trials
- 0
- Pancreatic cancer grants
- 0
- Collaborators
- 61
2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers
Papers 13
- Sequential nimotuzumab plus gemcitabine and nab-paclitaxel chemotherapy followed by irreversible electroporation in advanced pancreatic ductal adenocarcinoma: … Co-author DOI 10.20892/j.issn.2095-3941.2025.0848↗
- Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma. Co-author DOI 10.3389/fimmu.2026.1715761↗
- Combination of imaging features on pancreatic CT for predicting early recurrence after upfront pancreatoduodenectomy of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejro.2025.100672↗
- Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Co-author DOI 10.1126/sciadv.adk1827↗
- A CT Radiomics-Based Risk Score for Preoperative Estimation of Intraoperative Superior Mesenteric-Portal Vein Involvement in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-022-12664-0↗
- A Single-Cell Atlas of Tumor-Infiltrating Immune Cells in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1016/j.mcpro.2022.100258↗
- Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled… Co-author DOI 10.1016/j.prro.2022.02.009↗
- A four oxidative stress gene prognostic model and integrated immunity-analysis in pancreatic adenocarcinoma. First author DOI 10.3389/fonc.2022.1015042↗
- Analysis of radiotherapy impact on survival in resected stage I/II pancreatic cancer patients: a population-based study Co-author DOI 10.21203/rs.3.rs-126795/v2↗
- Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1042/bsr20201190↗
- An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocar… Co-author DOI 10.18632/oncotarget.27586↗
- Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.12834↗
- Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. Co-author DOI 10.1016/j.prro.2011.06.009↗
Closest collaborators
The 25 strongest of 61 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Daniel A. Laheru · 5 shared papers, 2012–2026
- Paper Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-C… DOI 10.3389/fimmu.2026.1715761↗
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma… DOI 10.1016/j.prro.2022.02.009↗
- Lei Zheng · 4 shared papers, 2012–2026
- Paper Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-C… DOI 10.3389/fimmu.2026.1715761↗
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma… DOI 10.1016/j.prro.2022.02.009↗
- Amol Kumar Narang · 4 shared papers, 2012–2026
- Paper Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-C… DOI 10.3389/fimmu.2026.1715761↗
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma… DOI 10.1016/j.prro.2022.02.009↗
- Elizabeth M. Jaffee · 4 shared papers, 2012–2026
- Paper Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-C… DOI 10.3389/fimmu.2026.1715761↗
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in pati… DOI 10.18632/oncotarget.27586↗
- Dung Thi Le · 4 shared papers, 2012–2026
- Paper Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-C… DOI 10.3389/fimmu.2026.1715761↗
- Paper Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma… DOI 10.1016/j.prro.2022.02.009↗
- Paper An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in pati… DOI 10.18632/oncotarget.27586↗
- Fang-Ming Chen · 2 shared papers, 2023–2025
- Paper Combination of imaging features on pancreatic CT for predicting early recurrence after upfront pancreatoduodenectomy of… DOI 10.1016/j.ejro.2025.100672↗
- Paper A CT Radiomics-Based Risk Score for Preoperative Estimation of Intraoperative Superior Mesenteric-Portal Vein Involveme… DOI 10.1245/s10434-022-12664-0↗
- Yongping Zhou · 2 shared papers, 2023–2025
- Paper Combination of imaging features on pancreatic CT for predicting early recurrence after upfront pancreatoduodenectomy of… DOI 10.1016/j.ejro.2025.100672↗
- Paper A CT Radiomics-Based Risk Score for Preoperative Estimation of Intraoperative Superior Mesenteric-Portal Vein Involveme… DOI 10.1245/s10434-022-12664-0↗
- Ana De Jesus-Acosta · 2 shared papers, 2020–2026
- Paper Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-C… DOI 10.3389/fimmu.2026.1715761↗
- Paper An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in pati… DOI 10.18632/oncotarget.27586↗
- Joseph Michael Herman · 3 shared papers, 2012–2024
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma… DOI 10.1016/j.prro.2022.02.009↗
- Paper Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemorad… DOI 10.1016/j.prro.2011.06.009↗
- Jin Peng He · 2 shared papers, 2022–2024
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma… DOI 10.1016/j.prro.2022.02.009↗
- Gui-Xue Dai · 1 shared paper, 2025
- Shuanglin Zhang · 1 shared paper, 2025
- Yong Xu · 1 shared paper, 2026
- Yi Liu · 1 shared paper, 2026
- Tongguo Si · 1 shared paper, 2026
- Chuntao Gao · 1 shared paper, 2026
- Jihui Hao · 1 shared paper, 2026
- Elizabeth D Thompson · 1 shared paper, 2026
- Arielle Rose Urman · 1 shared paper, 2026
- Richard Andrew Burkhart · 1 shared paper, 2026
- Yong Yan · 1 shared paper, 2023
- Dong Han · 1 shared paper, 2021
- Qi Fu · 1 shared paper, 2021
- Timothy Michael Pawlik · 2 shared papers, 2012–2022
- Paper Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma… DOI 10.1016/j.prro.2022.02.009↗
- Paper Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemorad… DOI 10.1016/j.prro.2011.06.009↗
- Robert A. Anders · 1 shared paper, 2024
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.